MARK2 and Miyoshi myopathy: The activating mutations in the RAS/RAF/MEK/ERK/MAPK pathway are identified in up to 50% of newly diagnosed MM patients [16], and the serine-threonine kinase BRAF is mutated in 8-12% of MM patients at diagnosis, with V600E as the most common BRAF mutation [16, 20].